Drug companies involved in TrumpRx boosted lobbying by 23% ahead of program’s launch
The 17 companies spent nearly $134 million as they pressed for pricing and tariff concessions while the White House shaped TrumpRx.
- The 17 pharmaceutical companies anchoring TrumpRx poured nearly $134 million into federal lobbying in 2025, a nearly 23% surge that outpaced the broader industry as the White House's prescription drug-pricing program was being shaped.
- Most-Favored-Nation pricing initiatives prompted companies to lobby heavily in exchange for trade concessions, including 0% tariffs through Jan. 20, 2029, aimed at forcing U.S. drug prices toward global levels.
- Eli Lilly increased lobbying spending nearly 33% to $11.2 million, while Bristol Myers Squibb nearly doubled its spending to more than $10 million as their blockbuster drugs faced steep negotiated price cuts.
- More than 60% of the 500-plus lobbyists hired were revolving-door professionals with government backgrounds. Omer Unsal, an associate professor at Merrimack College, noted this concentration reflects broader industry trends of former officials cycling into private advocacy roles.
- Industry-Wide lobbying shows no signs of slowing; first-quarter 2026 reports revealed spending topped $131 million, a 5.7% year-over-year increase, as the Pharmaceutical Research & Manufacturers of America continued monitoring 73 separate pieces of legislation.
12 Articles
12 Articles
Drug companies involved in TrumpRx boosted lobbying by 23% ahead of program’s launch - Hillsboro Sentry Enterprise
Drug companies involved in TrumpRx boosted lobbying by 23% ahead of program’s launchThe 17 pharmaceutical companies anchoring TrumpRx, the White House’s new prescription drug-pricing program, poured more than $130 million into federal lobbying in 2025 — a nearly 23% surge that outpaced the broader industry as the plan was being shaped behind the scenes.Those companies accounted for more than a quarter of the record $457.3 million spent on lobbyi…
Drug companies involved in TrumpRx boosted lobbying by 23% ahead of program’s launch - The Mexico Ledger
Drug companies involved in TrumpRx boosted lobbying by 23% ahead of program’s launchThe 17 pharmaceutical companies anchoring TrumpRx, the White House’s new prescription drug-pricing program, poured more than $130 million into federal lobbying in 2025 — a nearly 23% surge that outpaced the broader industry as the plan was being shaped behind the scenes.Those companies accounted for more than a quarter of the record $457.3 million spent on lobbyi…
Drug companies involved in TrumpRx boosted lobbying by 23% ahead of program’s launch - Seward Independent
Drug companies involved in TrumpRx boosted lobbying by 23% ahead of program’s launchThe 17 pharmaceutical companies anchoring TrumpRx, the White House’s new prescription drug-pricing program, poured more than $130 million into federal lobbying in 2025 — a nearly 23% surge that outpaced the broader industry as the plan was being shaped behind the scenes.Those companies accounted for more than a quarter of the record $457.3 million spent on lobbyi…
Coverage Details
Bias Distribution
- 83% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
